Poster Session 1

Friday, 13 December 2013: 12:30 - 13:30
Michigan Ballroom (Westin - Michigan Avenue)
Chairperson:   Michael Foggs (United States)
1000
1000: Efficacy and Safety of Specific Sublingual Immunotherapy with Carbamylated Allergoid Tablets of Ragweed Pollen: A Dose-Ranging Study Enrico Compalati (Italy)
1001
1001: ALLERGENIUS®: an Expert System for the Interpretation of Allergen Microarrays | G. Walter Canonica (Italy)
1002
1002: Galectin-3 as Predictive Biomarker of Airways Remodeling Modulation in Omalizumab Treated Severe Asthma Patients G. Walter Canonica (Italy)
1003
1003: Omalizumab is Effective in Allergic and Nonallergic Patients | Claus Bachert (Sweden)
1004
1004: The Effect of B7-H3 on CD4+ T Lymphocyte Activation in Vitro Jun Sik Lee (South Korea)
1005
1005: Analysis of the mechanism of the allergen immunotherapy in Japanese cedar pollinosis | Takenori Haruna (Japan)
1006
1006: Baicalin From Scutellaria baicalensis Impairs Th1 Polarization Through Inhibition of Dendritic Cell Maturation Jun Sik Lee (South Korea)
1007
1007: Universal Allergen Particle Generation for Inhaled Allergen Challenges in the Fraunhofer Environmental Challenge Chamber (ECC) | Jens M Hohlfeld (Germany)
1008
1008: Dialyzable Leukocyte Extracts as Adjuvant Treatment for Allergic Rhinitis | Toni Angela Homberg (Mexico)
1009
1009: AAAAI Survey on Allergen Immunotherapy (AIT) in Patients withSpecific Medical Conditions | Désirée Larenas-Linnemann (Mexico)
1010
1010: AAAAI Membership Experience with Venom Immunotherapy in Chronic Medical Conditions, Pregnancy and Young Children Désirée Larenas-Linnemann (Mexico)
1011
1011: Potential Immunogenetic Associations Between Atopy and Metabolic Syndrome In Children Laura Vidal (Mexico)
1012
1012: Safety and Efficacy Of Omalizumab In 10 Children With Asthma and Other Allergic Comorbidities Ana Célia Costa (Portugal)
1013
1013: IL-4R Alpha Antibody Inhibits IgE Production and Airway Remodeling In Mouse Model Of House Dust Mite-Induced Eosinophilic Asthma | Ludmila Kelly (United States)
1014
1014: Omalizumab Efficiency In Patients With Allergic Rhinitis and Chronic Sinusitis Lorena Rangel-Garza (Mexico)
1015
1015: : A Semi-rational Approach to Obtain a Thermostable Ionic Liquid Tolerant Bacterial Laccase Through Π- Type Interactions | Farideh Ghazi (Iran)
1016
1016: A Novel Peanut Allergoid Is Safe and Effective In a Murine Immunotherapy Model For Peanut Allergy | Hans Van Schijndel (Netherlands)
1017
1017: Preclinical and Clinical Findings: Role Of Periostin, IL-13, Lebrikzumab and Corticosteroid Resistance | Robert Townley (United States)
1018
1018: Evaluation Of CCR3 As a Basophil Activation Marker | Aaruni Khanolkar (United States)
1019
1019: Novel Allergy Vaccine Delivery System For Poison Ivy Urushiol (PI) and Peanut (PN) | Robert Coifman (United States)
1020
1020: Efficacy and Safety Of Sublingual Specific Immunotherapy With Pru p 3 In a Portuguese Population - Clinical and Immunological Evaluation During 12 Months | Ana Célia Costa (Portugal)
1021
1021: Use Of Paper Filter Discs For Measurement Of Local Biomarkers Of Nasal Mucosal Inflammation | Margot Berings (Belgium)
1022
1022: Angioedema and Angioedema Management From Asteria II: A Clinical Trial To Evaluate The Efficacy and Safety Of Omalizumab In Patients With Chronic Idiopathic/Spontaneous Urticaria (CIU/CSU) Who Remain Symptomatic Despite H1 Antihistamine Treatment | James Zazzali (United States)
1023
1023: Dupilumab Suppresses Th2 Inflammation In Adult Asthma and Atopic Dermatitis | Brian Swanson (United States)
1024
1024: Accelerated Healing Of Full-Thickness Cutaneous Wound Using Purified Apitoxin From Asiatic Honey Bee (Apis cerana Fabricius) | Hua Chen (China)
1025
1025: Introduction To The Clinical Practice Of Molecular Allergology | Guy Tropper (Canada)
1026
1026: Randomized Clinical Trial to Evaluate Oral Dializable Leukocyte Extracts as Immunemodulator Treatment in Atopic Dermatitis Jorge Galicia Carreón (Mexico)
See more of: Poster Sessions
<< Previous Session | Next Session >>